Early Recurrence of Ischaemic Stroke of Cardioembolic Cause and Delayed Anticoagulation: a Case Report

Overview

Journal Drugs Context

Specialty Pharmacology

Date 2022 Apr 25

PMID 35462640

Authors

Agnes Aghetti

Peggy Reiner

Affiliations

Soon will be listed here.

Abstract

Introduction: Anticoagulation therapy is used for the management of atrial fibrillation to prevent new clots from developing. However, neurologists face the challenge of when to initiate/reintroduce treatment after a recent episode of stroke without increasing haemorrhagic risk, especially if the stroke is large and/or complicated with haemorrhagic transformation.

Case Presentation: This report describes the case of a 72-year-old man who had an ischaemic stroke of the right posterior cerebral artery. The patient had permanent atrial fibrillation, discovered in hospital. He was not on chronic anticoagulation therapy before stroke. His anticoagulation therapy was postponed due to a haemorrhagic lesion, leading to new ischaemic stroke. The patient suddenly had right hemiplegia with aphasia for which a mechanical thrombectomy was performed but complicated by embolization into the left posterior cerebral artery with failure of thromboaspiration of this clot. Finally, the patient presented with intracranial hypertension due to ischaemic lesions and died 3 days after his readmission.

Conclusion: When to start anticoagulation therapy after ischaemic stroke is an unresolved question but should be discussed at least twice weekly in a stroke unit based on the clinical evolution of the patient.

References

Lindley R, Wardlaw J, Sandercock P, Rimdusid P, Lewis S, Signorini D . Frequency and risk factors for spontaneous hemorrhagic transformation of cerebral infarction. J Stroke Cerebrovasc Dis. 2007; 13(6):235-46. DOI: 10.1016/j.jstrokecerebrovasdis.2004.03.003. View

Whiteley W, Bruins Slot K, Fernandes P, Sandercock P, Wardlaw J . Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke. 2012; 43(11):2904-9. DOI: 10.1161/STROKEAHA.112.665331. View

Paciaroni M, Agnelli G, Falocci N, Caso V, Becattini C, Marcheselli S . Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing: The RAF Study. Stroke. 2015; 46(8):2175-82. DOI: 10.1161/STROKEAHA.115.008891. View

Paciaroni M, Bandini F, Agnelli G, Tsivgoulis G, Yaghi S, Furie K . Hemorrhagic Transformation in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Time to Initiation of Oral Anticoagulant Therapy and Outcomes. J Am Heart Assoc. 2018; 7(22):e010133. PMC: 6404429. DOI: 10.1161/JAHA.118.010133. View

Caso V, Masuhr F . A Narrative Review of Nonvitamin K Antagonist Oral Anticoagulant Use in Secondary Stroke Prevention. J Stroke Cerebrovasc Dis. 2019; 28(9):2363-2375. DOI: 10.1016/j.jstrokecerebrovasdis.2019.05.017. View

De Marchis G, Seiffge D, Schaedelin S, Wilson D, Caso V, Acciarresi M . Early versus late start of direct oral anticoagulants after acute ischaemic stroke linked to atrial fibrillation: an observational study and individual patient data pooled analysis. J Neurol Neurosurg Psychiatry. 2021; 93(2):119-125. DOI: 10.1136/jnnp-2021-327236. View

Hart R, Benavente O, McBride R, Pearce L . Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999; 131(7):492-501. DOI: 10.7326/0003-4819-131-7-199910050-00003. View

Adams Jr H, Bendixen B, Kappelle L, Biller J, Love B, Gordon D . Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24(1):35-41. DOI: 10.1161/01.str.24.1.35. View

van Latum J, Koudstaal P, Venables G, van Gijn J, Kappelle L, Algra A . Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with nonrheumatic atrial fibrillation. European Atrial Fibrillation Trial (EAFT) Study Group. Stroke. 1995; 26(5):801-6. DOI: 10.1161/01.str.26.5.801. View

10.

Gage B, Waterman A, Shannon W, Boechler M, Rich M, Radford M . Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285(22):2864-70. DOI: 10.1001/jama.285.22.2864. View

11.

Powers W, Rabinstein A, Ackerson T, Adeoye O, Bambakidis N, Becker K . Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American.... Stroke. 2019; 50(12):e344-e418. DOI: 10.1161/STR.0000000000000211. View

12.

Pisters R, Lane D, Nieuwlaat R, de Vos C, Crijns H, Lip G . A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138(5):1093-100. DOI: 10.1378/chest.10-0134. View

13.

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B . 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38):2893-2962. DOI: 10.1093/eurheartj/ehw210. View

14.

Paciaroni M, Agnelli G, Micheli S, Caso V . Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke. 2007; 38(2):423-30. DOI: 10.1161/01.STR.0000254600.92975.1f. View

15.

Yaghi S, Trivedi T, Henninger N, Giles J, Liu A, Nagy M . Anticoagulation Timing in Cardioembolic Stroke and Recurrent Event Risk. Ann Neurol. 2020; 88(4):807-816. PMC: 8259451. DOI: 10.1002/ana.25844. View